Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04027309
Title	A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)
Acronym	HOVON 156 AML
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications	myelodysplastic syndrome acute myeloid leukemia
Therapies	Midostaurin Gilteritinib
Age Groups:	adult \| senior
Covered Countries	SWE \| NOR \| NLD \| LUX \| LTU \| IRL \| FRA \| FIN \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS